CompletedISRCTN76555175
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
Interventional studyAges 17+CanadaBipolarity
Understand this study
Who was this study for?
Listed age limits: from 17 years.
- Listed locations
- Vancouver, CanadaSee all locations and recruitment
- Activities
- Medication and placebo comparator listed across study groups · Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJanuary 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 159
- Sponsor
- University of British Columbia
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- Over 17 Years
- Official registry ID
- ISRCTN76555175
- Official title
Show the full official title
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
Recruitment & locations
CompletedVancouver
Questions about this study
Who is behind this study?
The study sponsor is University of British Columbia, a university.
Did this study involve medication?
Yes. The study involved medication, including valproate, lithium, Risperidone and Olanzapine.
Who was this study for?
Listed age limits: from 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02363738
12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
United States, Canada
CompletedNCT00188942
A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolarity
Canada
CompletedNCT05328297
JNJ-55308942 for depression in bipolarity
Researchers compared JNJ-55308942 and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.